Entry Point Capital, LLC Larimar Therapeutics, Inc. Transaction History
Entry Point Capital, LLC
- $221 Million
- Q4 2024
A detailed history of Entry Point Capital, LLC transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 54,281 shares of LRMR stock, worth $136,788. This represents 0.09% of its overall portfolio holdings.
Number of Shares
54,281
Previous 18,236
197.66%
Holding current value
$136,788
Previous $119,000
73.95%
% of portfolio
0.09%
Previous 0.07%
Shares
3 transactions
Others Institutions Holding LRMR
# of Institutions
125Shares Held
66.8MCall Options Held
500KPut Options Held
61.2K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$53.5 Million2.01% of portfolio
-
Janus Henderson Group PLC London, X06.44MShares$16.2 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$15.2 Million0.37% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.65MShares$11.7 Million7.6% of portfolio
-
Goldman Sachs Group Inc New York, NY4.15MShares$10.5 Million0.0% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $109M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...